KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Non-Current Debt (2016 - 2020)

Nektar Therapeutics (NKTR) has 9 years of Non-Current Debt data on record, last reported at $254.8 million in Q1 2020.

  • For Q1 2020, Non-Current Debt rose 3.0% year-over-year to $254.8 million; the TTM value through Mar 2020 reached $254.8 million, up 3.0%, while the annual FY2019 figure was $250.0 million, 1.24% up from the prior year.
  • Non-Current Debt reached $254.8 million in Q1 2020 per NKTR's latest filing, up from $250.0 million in the prior quarter.
  • Across five years, Non-Current Debt topped out at $254.8 million in Q1 2020 and bottomed at $242.1 million in Q1 2016.
  • Average Non-Current Debt over 5 years is $246.0 million, with a median of $245.6 million recorded in 2018.
  • Peak YoY movement for Non-Current Debt: surged 94.05% in 2016, then grew 0.71% in 2019.
  • A 5-year view of Non-Current Debt shows it stood at $243.5 million in 2016, then grew by 0.72% to $245.2 million in 2017, then grew by 0.71% to $247.0 million in 2018, then grew by 1.24% to $250.0 million in 2019, then grew by 1.92% to $254.8 million in 2020.
  • Per Business Quant database, its latest 3 readings for Non-Current Debt were $254.8 million in Q1 2020, $250.0 million in Q4 2019, and $248.3 million in Q3 2019.